皮下注射达雷妥尤单抗联合标准方案治疗多发性骨髓瘤:PLEIADES II期研究
PLEIADES是一项开放标签II期研究,评估皮下注射达雷妥尤单抗(DARA SC)联合标准方案治疗多发性骨髓瘤(MM)。共199例患者接受治疗,分为D-VRd(适合移植初诊MM)、D-VMP(不适合移植初诊MM)和D-Rd(复发难治MM)三组。
要点
- DARA SC联合标准方案在各线MM中均显示与静脉制剂相当的临床活性。
核心结论
- 皮下注射达雷妥尤单抗联合标准方案治疗多发性骨髓瘤显示出与静脉制剂相当的临床活性,输注相关反应率低且给药时间缩短。
研究设计与样本
- 开放标签II期PLEIADES研究,共纳入199例多发性骨髓瘤患者,分为D-VRd组(n=67)、D-VMP组(n=67)和D-Rd组(n=65)。
临床怎么用
- 皮下注射达雷妥尤单抗联合标准方案可用于适合移植初诊、不适合移植初诊及复发难治多发性骨髓瘤患者。
- 皮下给药可缩短给药时间至5分钟,且输注相关反应发生率低,便于临床实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Daratumumab is a CD38-targeting monoclonal antibody approved for intravenous (IV) infusion for multiple myeloma (MM). We describe the Phase II PLEIADES study of a subcutaneous formulation of daratumumab (DARA SC) in combination with standard-of-care regimens: DARA SC plus bortezomib/lenalidomide/dexamethasone (D-VRd) for transplant-eligible newly diagnosed MM (NDMM); DARA SC plus bortezomib/melphalan/prednisone (D-VMP) for transplant-ineligible NDMM; and DARA SC plus lenalidomide/dexamethasone (D-Rd) for relapsed/refractory MM. In total, 199 patients were treated (D-VRd, n = 67; D-VMP, n = 67; D-Rd, n = 65). The primary endpoints were met for all cohorts: the ≥very good partial response (VGPR) rate after four 21-day induction cycles for D-VRd was 71·6% [90% confidence interval (CI) 61·2-80·6%], and the overall response rates (ORRs) for D-VMP and D-Rd were 88·1% (90% CI 79·5-93·9%) and 90·8% (90% CI 82·6-95·9%). With longer median follow-up for D-VMP and D-Rd (14·3 and 14·7 months respectively), responses deepened (ORR: 89·6%, 93·8%; ≥VGPR: 77·6%, 78·5%), and minimal residual disease-negativity (10-5 ) rates were 16·4% and 15·4%. Infusion-related reactions across all cohorts were infrequent (≤9·0%) and mild. The median DARA SC administration time was 5 min. DARA SC with standard-of-care regimens demonstrated comparable clinical activity to DARA IV-containing regimens, with low infusion-related reaction rates and reduced administration time.
引用
- Chari A, Rodriguez-Otero P, McCarthy H, et al. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. Br J Haematol. 2020. PMID: 33216361. doi:10.1111/bjh.16980
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。